Zacks Research Analysts Decrease Earnings Estimates for IRWD

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Zacks Research reduced their Q3 2026 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, March 26th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings of $0.07 per share for the quarter, down from their prior estimate of $0.08. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2026 earnings at $0.06 EPS and FY2026 earnings at $0.23 EPS.

Several other equities analysts have also recently commented on the stock. Craig Hallum lowered their price target on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. Finally, JMP Securities cut their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $8.60.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD opened at $1.46 on Friday. The company has a market capitalization of $233.64 million, a PE ratio of -48.67 and a beta of 0.37. The company’s 50 day moving average price is $2.09 and its 200 day moving average price is $3.41. Ironwood Pharmaceuticals has a 52 week low of $1.34 and a 52 week high of $9.01.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.08). The business had revenue of $90.55 million for the quarter, compared to analysts’ expectations of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the completion of the transaction, the chief executive officer now owns 1,160,634 shares of the company’s stock, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now owns 554,007 shares of the company’s stock, valued at $975,052.32. This represents a 6.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 192,381 shares of company stock worth $338,591. Company insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp raised its position in Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock valued at $40,870,000 after buying an additional 677,024 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Ironwood Pharmaceuticals by 47.4% during the 4th quarter. Deutsche Bank AG now owns 1,567,535 shares of the biotechnology company’s stock valued at $6,944,000 after buying an additional 504,336 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Ironwood Pharmaceuticals by 5.5% during the 4th quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock worth $40,163,000 after acquiring an additional 469,043 shares during the period. Pacer Advisors Inc. grew its stake in shares of Ironwood Pharmaceuticals by 4.0% during the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after acquiring an additional 450,949 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Ironwood Pharmaceuticals in the 4th quarter worth about $1,888,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.